Marianne E. Cinat

Picture of Marianne E. Cinat
Professor, Department of Surgery, Division of Trauma, Burns, Critical Care and Acute Care Surgery
School of Medicine
Director, UC Irvine Regional Burn Center
School of Medicine
M.D., University of Michigan Medical School, 1990
B.S., University of Michigan, Ann Arbor, MI, 1987, Bachelor of Science, with distinction
M. Cinat Memorial Fund
University of California, Irvine

,
Research Interests
Trauma, Surgical Critical Care, Intensive Care, Research, General Surgery, Ventilator associated pneumonia, Intraabdominal abscess
Academic Distinctions
Specialty Board Status:
American Board of Surgery, Diplomat 1997
Surgical Critical Care, Board Certification 1998
Re-Certification, American Board of Surgery 2006
Re-Certification, Surgical Critical Care 2007


Qualifications:
NBME Certification 1991
California State Board of Medical Assurance 1992 - present
Drug Enforcement Administration 1992 - present
Basic Life Support Certification 1992 - present
Advanced Cardiac Life Support Certification 1992 - present
Advanced Trauma Life Support Certification 1995
General Surgery, Board Certification 1997
Fluoroscopy Supervisor and Operator Permit 1997 - present
Advanced Burn Life Support Certification 1997
Advanced Trauma Life Support Instructor 1998 - present
Surgical Critical Care, Board Certification 1998
Pediatric Advanced Life Support 2000
Advanced Burn Life Support Instructor 2000 - present
National Faculty Advanced Burn Life Support 2003 - present
Fellow, American College of Surgeons 2003 - present
General Surgery, Board Recertification 2006
Surgical Critical Care, Board Recertification 2007


Professional Community Service:
Orange County Burn Association, Board of Directors 2000 - present
Orange County Surgical Society
Program Chairperson 2002, 2003
Treasurer 2003
President 2004
American College of Surgeons, Southern California Chapter
Young Surgeon Representative 2000
Assistant Program Chairperson 2002
Associate Program Chairperson 2003
Program Chairperson 2004
Board of Directors 2005 – present
Secretary / Treasurer 2009 - 2010
Pacific Coast Surgical Association, Planning Committee 2005
Associate Examiner American Board of Surgery 2002, 2006
American College of Surgeons
Board of Governors 2007 - 2009
Committee on Surgical Infections 2007 – 2009
& Environmental Risk
Ad Hoc Committee on Transfusions 2008 - 2009
Surgical Critical Care Certifying and Recertification
Examination Consultant 2008 – present
American Burn Association
Organization & Delivery of Burn Care Committee 2008 – 2011


Honors and Awards:
Branstrom Award (top 5% of freshman 1984
students at the University of Michigan)
Class Honors, University of Michigan 1983-1987
Faculty Career Development Award 1997
American Medical Women’s Association
Medical Student Teaching Award 1998
Plenary Award 1999
(American Federation for Medical Research)
(for supervised work of undergraduate
student, David Choi)
Committee on Research Grant 1999
UCI College of Medicine
Undergraduate Research Opportunity Grant 1999
International Association of Firefighters Grant 1999
Plastic Surgery Education Foundation 1999
Scholarship Essay Contest
(for supervised work of resident, S. Iraniha)
John E. Connolly Resident Teaching Award 1999
Undergraduate Research Opportunity Grant 2000
Young Surgeon Representative, Southern 2000
California American College of Surgeons
American College of Surgeons, Committee on Trauma 2000
Region IX, Resident Paper Competition, 2nd Place
Basic Science Category, Las Vegas, Nevada
“The Effects of The Lazaroid U-74389G on Lipid
Peroxidation and Nitric Oxide Metabolism.”
(for supervised work of Christopher Lane, M.D.)
American College of Surgeons, Committee on Trauma 2003
Region IX, Resident Paper Competition,
Honorable Mention , Clinical Science Category, Las Vegas, Nevada
“The Impact of Ventilator-Associated Pneumonia on
Survival in Elderly Trauma Patients.”
(for supervised work of Michael Peck, M.D.)
Society of Air Force Clinical Surgeons 2003
Abstract: “Burn Injury Results in Altered Leukocyte
Expression of Apoptosis Regulating Proteins”,
selected as 2nd place finalist for the General Paul Myers
Research Award in basic science.
(for supervised work of Michael Peck, M.D.)
American College of Surgeons, Committee on Trauma 2004
Region IX, Resident Paper Competition,
“Predictors of Morbidity and Mortality in Patients with
Duodenal Injuries”. Abstract presented in Reno, Nevada.
(for supervised work of Trung Bui, M.D.)
Southern California American College of Surgeons 2005
Resident Paper Competition, Third Place,
“Predictors of Morbidity and Mortality in Patients with
Duodenal Injuries”. Presented in Santa Barbara, CA.
(for supervised work of Sergio Huerta, M.D.)
Best Doctors in America Distinction 2007
University Research Opportunity Grant 2008
Awarded to Fariba Jafari under the supervision of
Dr. Marianne Cinat and Dr. Andrew Barleben following
Abstract presentation, “Implementation of an algorithm for
obtaining pelvic radiographs in blunt trauma patients
decreases costs without adverse patient outcomes”,
San Francisco, California, American College of Surgeons
94th Clinical Congress.
Appointments
Professor of Clinical Surgery, June 2009 - present
University of California, Irvine

Associate Professor of Clinical Surgery, June 2003-2009
Univeristy of California, Irvine

Assistant Professor of Surgery in Residence, July 1997-June 2003
University of California, Irvine

Director, Surgical Research (Trauma/Crit Care), July 1996-present
University of California, Irvine

Director, Surgical Critical Care Fellowship, Dec 1998-present
University of California, Irvine

Director, Burn Intensive Care Unit, July 1998-present
University of California, Irvine
Publications
1. Gilsdorf JR, Judd WJ, Cinat ME. Relationship of Haemophilus influenzae type b pilus structure and adherence to human erythrocytes. Infection and Immunity, 1989, 57 (10):3259-3260.
2. Daughters KR, Cinat ME, Waxman KS. Amrinone improves survival in hemorrhagic shock. American Surgeon, 1994, 60 (10):728-732.
3. Cinat ME, Waxman KS, Granger GA, Pearce W. Annas C, Daughters KR. Trauma causes sustained elevation of soluble tumor necrosis factor receptors. Journal of the American College of Surgeons, 1994, 179(5):529-537.
4. Cinat ME, Waxman KS, Vaziri ND, Daughters K, Yousefi S, Scannell G, Tominaga GT. Soluble cytokine receptors and receptor antagonists are sequentially released after trauma. Journal of Trauma, 1995, 39(1):112-118, discussion 118-120.
5. Daughters K, Waxman KS, Greenway S, Aswani S, Cinat ME, Scannell G, Tominaga GT. Ethanol added to resuscitation improves survival in an experimental model of hemorrhagic shock. American Surgeon, 1995, 61(10):896-903.
6. Cinat ME, Wilson SE. Management of renal artery aneurysms. Renal disease and the Vascular Surgeon. Seminars in Vascular Surgery, 1996, 9(3): 236-244.
7. Cinat ME, Lane CT, Pham HV, Nguyen T, Lee AL, Wilson SE, Gordon IL. Helical CT in the Pre-Operative Evaluation of Carotid Artery Stenosis. Journal of Vascular Surgery, 1998, 28(2):290-300.
8. Cinat ME, DiStante AG, Burchell SA: Perioperative Care of Patients With Cirrhosis, Problems in General Surgery 1998, 15(4):39-51.
9. Cinat ME, Pham H, Vo D, Gordon I, Wilson SE. Improved Imaging of the Carotid Artery Bifurcation with Helical CT Angiography. Annals of Vascular Surgery, 1999, 13(2):178-183.
10. Cinat ME, Hopkins J, Wilson SE. Prospective Evaluation and Predictive Factors for PTFE Graft Patency in Hemodialysis Patients. Annals of Vascular Surgery, 13(2):191-198, March 1999.
11. Wallace WC, Cinat ME, Gornick WB, Lekawa ME, Wilson SE. Nosocomial Infections in the Surgical Intensive Care Unit: A Difference Between Trauma And Surgical Patients. American Surgeon, 1999, 10:987-990.
12. Cinat ME, Wallace CW, Nastanski F, West J, Sloan S, Ocariz J, Wilson SE. Improved Survival in Trauma Patients Following Massive Transfusion. Archives of Surgery, 1999, 134:964-970.
13. Cinat ME, Wilson SE. New Advances in the Use of Antimicrobial Agents in Surgery: Intraabdominal Infections. Journal of Chemotherapy, 1999, 11(6):453-463.
14. Iraniha S, Cinat ME, Vanderkam VM, Boyko A, Lee D, Jones J, Achauer BM. Determination of Burn Wound Depth With Non-Contact Ultrasound. J Burn Care Rehab, 2000, 21:333-38.
15. Wallace WC, Cinat ME, Nastanski F, Gornick SB, Wilson SE. New Epidemiology for Post-Operative Nosocomial Infections, American Surgeon, 2000, Sep, 66(9):874-8.
16. The Traumatic Shock Group, Cinat ME. Recombinant Humanized Monoclonal Antibody Against CD 18 (rhuMAbCD18) in Traumatic Hemorrhagic Shock: Results of a Phase II Clinical Trial. Journal of Trauma, 2000, 49(4): 611-9; discussion 619-20.
17. Cinat ME, Wilson SE, Podnos YD, et al: Eradication of a Multi-drug Resistant Acinetobacter from an Intensive Care Unit, Surgical Infections, 2001, (2):297-301.
18. Cinat ME, Wilson SE, Din AM: Determinants for Successful Percutaneous Image-Guided Drainage of Intraabdominal Abscess, Archives of Surgery, 2002, 137:845-9.
19. Kafie FE, Williams R, Tessier DJ, Cinat ME, Podnos Y, Lekawa ME, Wilson SE. Serial Abdominal Closure Technique (the “SAC” procedure). American Surgeon, 2003, 69(2):102-5.
20. Lane CT, Cohen AJ, Cinat ME. Management of Traumatic Abdominal Wall Hernia, American Surgeon , 2003, 69:73-76.
21. Cinat ME, Casalme C, Wilson SE, Pham H, Anderson P, CT Angiography Validates Duplex Sonographic Evaluation of Carotid Artery Stenosis. American Surgeon, 2003, 69:842-847.
22. Lane CT, Cinat ME. Letter to the Editor, “Management of Traumatic Abdominal Wall Hernia”, American Surgeon 2003, 69:73-6.
23. Cinat ME. Wilson SE, Lush S, Atkins C. Significant Correlation of Trauma Epidemiology With the Economic Conditions of a Community. Archives of Surgery, 2004, 139:1350-1355.
24. Hsu SC, Cinat ME. Survey Results of Common Products Used in Scar Management Among Burn Therapists,
J Burn Care Rehab, 2005, 26(2):S165.
25. Gibran NS, Greenhalgh DG, Lozano D, Luterman A, Herndon DN, Cinat ME, Gamelli RL, Foster KN, Miller SF. Assessment of Safety and Efficacy of Fibrin Sealant for Wound Healing in Subjects with Burn Wounds Requiring Skin Grafting, J Burn Care Rehab, 2005, 26(2):S30.
26. Codner P, Cinat ME. Massive Transfusion for Trauma is Appropriate. Trauma Care. Summer 2005, 15(3):148-152.
27. Huerta S, Bui T, Porral D, Lush S, Cinat ME. Predictors of Morbidity and Mortality in Patients with
Traumatic Duodenal Injuries. American Surgeon, 2005, 71(9):763-767.
28. Codner P, Obaid A, Porral D, Lush S, Cinat ME. Field Hypotension a Reliable Indicator of Significant
Injury in Trauma Patients who are Normotensive on Arrival to the Emergency Department. The American
Surgeon, 2005, 71(9):768-771.
29. Huerta S, Fairbanks T, Cinat ME. Incarcerated Vesicinguinal Hernia Presenting with Gross Hematuria.
Journal of the American College of Surgeons, 2005, 201(6):992-993.
30. Cinat ME, Carson J. Burns and Motor Vehicle Crashes . Topics Emergency Medicine, 2006, 28(1):56-67.
31. Hsu, SC, Kemp, J, Cinat, ME. Linear Elasticity of Upper Extremity Skin in Normal Individuals: Objective
Criteria for use in Skin Grafting and Post-Operative Splinting. J Burn Care Rehab, March 2006, 27(2):S145
32. Obaid A, Barleben A, Porral D, Lush S, Cinat ME. Utility of Plain Film Radiographs in Blunt Trauma
Patients in the Emergency Department”. American Surgeon. Oct 2006; 72(10):951-4.
33. Barrios C, Tran T, Malinoski D, Lekawa M, Dolich M, Lush S, Hoyt D, Cinat ME: Successful Management of
Blunt Traumatic Pneumothorax Without Tube Thoracostomy Despite Positive Pressure Ventilation. American Surgeon. October 2008; 74(10):958-961.
Grants
1. Effects of Drug Treatment on Controlled Ischemia in Rats To evaluate the Effect 1997-2001 Of Various Agents on Both Survival and Cytokine Production Following Hemorrhagic Shock. Principle Investigator
2. Role of Apoptosis in Immune Function in Trauma and Critically Ill Patients To Evaluate 1999-2002 Markers of Apoptosis in Leukocyte Cell Populations Following Injury. Principle Investigator
3. Ascending Dose, Parallel Group, Double-Blind, Placebo Controlled Dose Finding Study 1998-2000 Of rhuMAb CD18 in Patients With Traumatic Hemorrhagic Shock. A Phase II clinical $200,000 Study to Evaluate the Safety and Pharmacokinetics of a Monoclonal antibody to CD18 in the treatment of traumatic hemorrhagic shock. Principle Investigator
4. Incidence of Nasal Colonization with Mupirocin Resistant Staphylococcus Aureus. 1999-present Co-investigator
5. Utility of MAK195F in the Treatment of Septic Shock. A prospective study to 1998-1999 Determine the Safety and Efficacy of MAK195F in the Treatment of Septic Shock. Co-Investigator
6. Randomized Single-Blind Placebo-Controlled Trial To Evaluate the Pharmokinetics and 1996-1997 Immunologic Effects of Two Treatment Regimens of Bacteriocidal-Permeability Increasing Protein (rBPI 21) In Patients with Hemorrhage Due to Trauma. A prospective study to determine the safety and efficacy of a recombinant protein with both anti-endotoxin and anti-bacteriocidal properties. Co-Investigator
7. Efficacy of rHuEPO in the Critically Ill Patient: A Randomized, Double-Blind, 1999-2001 Placebo Controlled Trial. To evaluate the utility of rHuEPO in the treatment of anemia $221,485 in the intensive care unit patient. Protocol # - HS 99-1047 Principal Investigator
8. Use of Computed Tomographic Arteriography in the Evaluation of Carotid Disease 1997-present A retrospective study that compares traditional arteriography with the new technology of computed tomographic arteriography. Principle Investigator
9. A Multicenter Open-Label Study of the Safety and Efficacy of GAR 936 to Treat 1997-2001 Complicated Intraabdominal Infections in Hospitalized Patients. $101,112 Protocol # - 3074A1-202-US (IRB 2000-1211). Co-Investigator
10. A Multicenter, Randomized, Open-Label Comparison Study of the Safety and Efficacy 1999-2001 of the Safety and Efficacy of Two Intravenous Dosages of GAR 936 to Treat Complicated $81,134 Skin and Skin Structure Infections in Hospitalized Patients. Protocol # 3074A1-200-US (HS 99-2185). Co-Investigator
11. A Prospective, Multicenter, Double-Blind, Randomized Comparative Study to Evaluate 1998-2001 the Safety and Efficacy of MK 0826 versus Piperacillin/Tazobactam in the Treatment $125,260 of Complicated Intraabdominal Infections in Hospitalized Adults. Protocol # - 017-00 (HS 98-127).
12. A Prospective, Multicenter Trial Comparing MK0826 Versus Piperacillin/Tazobactam 1998-2001 in the Treatment of Complicated Skin and Skin Structure Infections. $123,340 (HS 98-126)
13. Randomized, Double-Blind, Multi-Center Study Comparing the Efficacy and 1997-2000 Safety of Piperacillin/ Tazobactam and Imipenen/Cilastatin Administered $70,218 Intravenously Every Six Hours to Treat Nosocomial Pneumonia in Hospitalized Patients. 0910a7-303-US, (HS 97-122)
14. Non-contact Ultrasound for Determination of Burn Wound Depth, 1999 International Association of Firefighters. $15,000 Co-Investigator
15. A Randomized, Parallel-group, Double-blind, Placebo controlled Clinical Trial Evaluating the Safety, Tolerance, Pharmacokinetics and Effectiveness of Angiotensin II (AI) in Treating Patients with Partial Thickness Burns. Protocol # - HS 96-632 Co-Investigator
16. A Clinical Trial to Evaluate the Topical Homeostatic Efficacy of Fibrin Sealant (Human) in Burn Patients Undergoing Skin Graft Procedures. Co-Investigator
17. The Disparity of Traffic Safety Knowledge Base Between Ethnic Groups in Southern California. Co-Investigator
18. A Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy 2003-2006 and Safety of Epoetin Alfa in Critically Ill Subjects. $267,499 Protocol # - EPO-ICU-002 Primary Investigator
19. A Multicenter Clinical Trial of the Effects of Topical Application of Cerium 2003-2006 Nitrate/Silver Sulfadiazine Cream Versus Silver Sulfadiazine Cream Alone $Pending in the Treatment of Burn Patients.
20. Compound: Fondaparinux Sodium. A multicenter, randomized, double-blind, 2002-2004 parallel group trial to demonstrate the efficacy of fondaparinux sodium in $101,522 association with Intermittent Pneumatic compression versus Intermittent Pneumatic Compression used along for the prevention of venous Thromboembolic events in patients undergoing major Abdominal surgery. Protocol # - EFC3558.
21. Retrospective Study of the EPO II Trauma Subpopulation to Evaluate the 2003-present Association Between Severity of Illness as Measured by ISS, TRISS, AIS 30,662 and Shock Severity Measures and the Effects of Epoetin Alfa Treatment on Study Outcomes RESIST (Retrospective Evaluation of Severity of Illness and Shock in Trauma).
22. A Study to Evaluate the Safety and Efficacy of Fibrin Sealant with 4IU/ML 2005-2006 Thrombin Vapor Heated, Solvent/Detergent Treated (FS 4IU VH S/D) to $60,000 Adhere Tissues and Improve Wound Healing. Protocol # 550201 Baxter Healthcare Corporation
23. A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Effect 2006-present of Recombinant Human Erythropoietin (Epoetin alfa; PROCRIT®) on Functional $119,990 Outcomes in Anemic, Critically Ill, Trauma Subjects. Protocol # PR04-15-001 Ortho Biotech Clinical Affairs, LLC
24. Linezolid in the Treatment of Subjects with Nosocomial Pneumonis Proven Dec. 2005-present to be Due to Methicillin-Resistant Staphylococcus Aureus. $72,760 Protocol # A5951001 Primary Investigator Sponsor: Pfizer
25. Prospective Evaluation of the Effects of Topical Therapy with Sulfamylon® Sept. 2006-present for 5% Topical Solution on Autograft Healing in Subjects with Thermal $84,343 Injuries Requiring Meshed Autografts: A Comparison to a Historical Control Group. Protocol # SMS-401 Primary Investigator Sponsor: Mylan Pharmaceuticals Inc.
26. A Pivotal Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled 2006 Study to Evaluate the Efficacy and Safety of TAK-242 in Adults with Sever Sepsis. $312,300 TAK-242 in Adults with Sever Sepsis. Protocol # TAK-242 Primary Investigator Sponsor: Takeda Research Development Center, Inc.
27. A Multicenter, Open-Label, Randomized Comparative Study Tigecycline vs. Ceftriaxone 2006-2007 Sodium plus Metronidazole for the Treatment of Patients with Complicated Intra-Abdominal $84,201 Infection. Protocol # 3074A1-400-WW (Protocol Amendment 2) HS# 2006-5007 Sponsor: Wyeth Research
28. A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of 2008-present TAK 242 versus Placebo in Subjects with Sepsis Induced Cardiovascular and Respiratory $269,080 Failure. Protocol HS #208-6381 Primary Investigator Sponsor: Takeda Pharmaceuticals
29. A Prospective, Randomized, Double-Blind, Double Dummy Multicenter Study to Assess 2008-present The Safety and Efficacy of Doripenem Compared with Imipenem in the Treatment of $132,461 Subjects with Ventilator Associated Pneumonia. Protocol HS# 208-6109 Primary Investigator Sponsor: Johnson & Johnson Pharmaceuticals
Professional Societies
Society of Critical Care Medicine
American College of Surgeons, Fellow
American College of Surgeons, SCS, Exec Committee
International Trauma Anesthesia and Crit Care Society
American Burn Association
Association of Women Surgeons
American Medical Association
Shock Society
Pacific Coast Surgical Association
American Association for the Surgery of Trauma
Other Experience
General Surgery Residency
University of California, Irvine Medical Center, Orange, CA 1990—1996
Surgical Critical Care Fellowship
University of California, Irvine Medical Center, Orange, CA 1997—1998
Graduate Programs
Critical Care Medicine (IM)
Surgical Critical Care (GS)
Research Centers
Director, Surgical Research (Trauma/Critical Care)
Last updated
05/23/2017